https://www.selleckchem.com/pr....oducts/pluripotin-sc
66, 95%CI = 0.46-0.95, = 0.025). Subgroup analysis in the matched cohort showed that patients could benefit more from LND if they were male, age 60 years, had no HBV infection, with ECOG score 2, CEA ≤5 ug/L, blood loss ≤400 ml, transfusion, major hepatectomy, resection margin ≥1 cm, tumor size 5cm, single tumor, mass-forming, no satellite, no MVI, and no perineural invasion (all 0.05). Furthermore, only patients with pathologically confirmed positive LNM were found to benefit from postoperative adjuvant therapy
Like
Comment
Share
